Dr Eitan Raveh (Vice President of Clinical Partnerships at NeuraLight)
ArticleEye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.